LFB Biomanufacturing is a CDMO specializing in the manufacture of recombinant proteins and monoclonal antibodies.

LFB Biomanufacturing

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Florence Kurth

Florenz Sartorius

Sartorius Aktiengesellschaft

France BioLead is an initiative that structures, pilots, animates, and promotes the French sector of bioproduction of biomedicines.

Metric
Company Name	LFB Biomanufacturing	Sartorius Aktiengesellschaft	France BioLead
Symbol		SRT
MSH ID	COM:LFBBIOMANUFACTURING	COM:SARTORIUS	FR:FRANCE-BIOLEAD
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Medical - Instruments & Supplies	Biotechnology
Country	FR	DE	FR
Stage
Employee Count		14.61K
Website	lfbbiomanufacturing.com	sartorius.com	france-biolead.fr
LinkedIn		sartorius
Founders

Metric
Market Cap		15.56B
Enterprise Value
Monthly Web Traffic		1.07M
Web Traffic Growth		1.47
Valuation
Raised Capital

Metric
Revenue		3.59B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.66B
EBITDA		890.51M
Operating Income		528.96M
Net Income		357.53M
EPS		5.23
Diluted EPS		5.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.46
Operating Profit Margin		0.16
EBITDA Margin		0.25
Net Profit Margin		0.09
Return on Equity		0.15
Return on Assets		0.03
Return on Capital Employed		0.07

COM:LFBBIOMANUFACTURING

LFB Biomanufacturing

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		41.01
P/B Ratio		8.67
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.48
EV Multiple		19.08

Metric
Days Sales Outstanding		42.10
Days Payables Outstanding		91.49
Days Inventory Outstanding		206.95
Operating Cycle		260.52
Cash Conversion Cycle		181.83
Asset Turnover		0.35

Metric
Operating Cash Flow		901.60M
Free Cash Flow		310.43M
Cash Flow to Debt		0.18
Operating Cash Flow/Sales		0.25
Free Cash Flow Yield		0.01

Metric
Cash & Equivalents		400.52M
Accounts Receivable		178.08M
Inventory		1.10B
Goodwill		3.61B
Debt to Capitalization		0.72
Debt to Assets		0.54
Current Ratio		1.49
Quick Ratio		1.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.05
SG&A to Revenue		0.05